Melatonin at the crossroads: Commentary on COVID and cognition

Abstract

In this commentary, we explore the frontier edge of the emerging potential role of the chronobiotic agent melatonin, in both the prevention and treatment, and in the amelioration of some of the newly identified pathological neurocognitive sequelae, of SARS-2-CoV infection (COVID-19 disease). In the process we review clinical evidence of benefit in these domains, suggesting the strong promise that melatonin appears to provide, with a highly favorable benefit/harm ratio of excellent tolerability, affordability and safety, and sufficiently compelling evidence of efficacy as to be actionable, in the here and now.